Anne Lambilliotte

Publications (9)37.35 Total impact

• Source

  Available from: Judith Landman-Parker

  Dataset: s1-ln10978013-1998934368-1939656818Hwf791939546IdV-198662806610978013PDF HI0001

  Stéphanie Gorde-Grosjean, Odile Oberlin, Thierry Leblanc, Hélène Pacquement, Jean Donadieu, Anne Lambilliotte, Mathias Schell, Florence Dommange, Martine Munzer, Catherine Paillard, Claudine Schmitt, Patrick Lutz, Christine Edan, Sophie Ansoborlo, Jean-Louis Stephan, Gérard Michel, Caroline Thomas, Yves Perel, Alain Robert, Judith Landman-Parker
• Article: Outcome of children and adolescents with recurrent/refractory classical Hodgkin lymphoma, a study from the Société Française de Lutte contre le Cancer des Enfants et des Adolescents (SFCE).

  Stéphanie Gorde-Grosjean, Odile Oberlin, Thierry Leblanc, Hélène Pacquement, Jean Donadieu, Anne Lambilliotte, Mathias Schell, Florence Dommange, Martine Munzer, Catherine Paillard, Claudine Schmitt, Patrick Lutz, Christine Edan, Sophie Ansoborlo, Jean-Louis Stephan, Gérard Michel, Caroline Thomas, Yves Perel, Alain Robert, Judith Landman-Parker
  [show abstract] [hide abstract]
  ABSTRACT: There is little data available regarding children and adolescents with Hodgkin lymphoma (HL) who relapse after combined-modality treatment, even though they have a substantial chance of cure. The purpose of this national retrospective study was to evaluate the outcome of patients with recurrent/refractory HL and determine adverse prognostic factors. From 1990 to 2006, 70 patients (median age 13·9 years) with refractory (n = 31) or first relapse (n = 39) HL were identified. Median time from end of treatment to relapse was 6 months (3-56). Relapses occurred in irradiated areas in 43/70 patients. Salvage therapy consisted of chemotherapy and 50 patients received high-dose chemotherapy with autologous stem cell transplantation. Radiotherapy was performed in 29 cases, tandem autologous transplantation in five and allograft in three. With a median follow-up of 40 months (2-140), significant prognostic factors were time to progression/relapse and response to therapy before autograft. Event-free survival and overall survival in patients with refractory disease, early relapse and late relapse were 35 ± 9%, 67 ± 11%, 76 ± 10% and 48 ± 11%, 89 ± 7% and 80 ± 10%, respectively. As progression <3 months was a major adverse prognostic factor, novel therapeutic approaches are needed for this group of patients. By contrast, patients have substantial chance of long term second remission in case of relapse >3 months.
  British Journal of Haematology 07/2012; 158(5):649-56. · 4.94 Impact Factor
• Article: Classification of and risk factors for hematologic complications in a French national cohort of 102 patients with Shwachman-Diamond syndrome.

  Jean Donadieu, Odile Fenneteau, Blandine Beaupain, Sandrine Beaufils, Florence Bellanger, Nizar Mahlaoui, Anne Lambilliotte, Nathalie Aladjidi, Yves Bertrand, Valérie Mialou, Christine Perot, Gérard Michel, Fanny Fouyssac, Catherine Paillard, Virginie Gandemer, Patrick Boutard, Jacques Schmitz, Alain Morali, Thierry Leblanc, Christine Bellanné-Chantelot
  [show abstract] [hide abstract]
  ABSTRACT: Background Patients with the Shwachman-Diamond syndrome often develop hematologic complications. No risk factors for these complications have so far been identified. The aim of this study was to classify the hematologic complications occurring in patients with Shwachman-Diamond syndrome and to investigate the risk factors for these complications. DESIGN AND METHODS: One hundred and two patients with Shwachman-Diamond syndrome, with a median follow-up of 11.6 years, were studied. Major hematologic complications were considered in the case of definitive severe cytopenia (i.e. anemia <7 g/dL or thrombocytopenia <20×10(9)/L), classified as malignant (myelodysplasia/leukemia) according to the 2008 World Health Organization classification or as non-malignant. RESULTS: Severe cytopenia was observed in 21 patients and classified as malignant severe cytopenia (n=9), non-malignant severe cytopenia (n=9) and malignant severe cytopenia preceded by non-malignant severe cytopenia (n=3). The 20-year cumulative risk of severe cytopenia was 24.3% (95% confidence interval: 15.3%-38.5%). Young age at first symptoms (<3 months) and low hematologic parameters both at diagnosis of the disease and during the follow-up were associated with severe hematologic complications (P<0.001). Fifteen novel SBDS mutations were identified. Genotype analysis showed no discernible prognostic value. Conclusions Patients with Shwachman-Diamond syndrome with very early symptoms or cytopenia at diagnosis (even mild anemia or thrombocytopenia) should be considered at a high risk of severe hematologic complications, malignant or non-malignant. Transient severe cytopenia or an indolent cytogenetic clone had no deleterious value.
  Haematologica 04/2012; 97(9):1312-1319. · 6.42 Impact Factor
• Source

  Available from: Martine Gardembas

  Article: Efficacy of vinblastine in central nervous system Langerhans cell histiocytosis: a nationwide retrospective study.

  Sophie Ng Wing Tin, Nadine Martin-Duverneuil, Ahmed Idbaih, Catherine Garel, Maria Ribeiro, Judith Landman Parker, Anne-Sophie Defachelles, Anne Lambilliotte, Mohamed Barkaoui, Martine Munzer, [......], Perrine Marec Berard, Ghislain Nokam Talom, Jean-Loup Pennaforte, Hubert Ducou Le Pointe, Marie-Anne Barthez, Gérard Couillault, Julien Haroche, Karima Mokhtari, Jean Donadieu, Khê Hoang-Xuan
  [show abstract] [hide abstract]
  ABSTRACT: Vinblastine (VBL) is the standard treatment for systemic Langerhans cell histiocytosis (LCH), but little is known about its efficacy in central nervous system (CNS) mass lesions. A retrospective chart review was conducted. Twenty patients from the French LCH Study Group register met the inclusion criteria. In brief, they had CNS mass lesions, had been treated with VBL, and were evaluable for radiologic response. The median age at diagnosis of LCH was 11.5 years (range: 1-50). Intravenous VBL 6 mg/m2 was given in a 6-week induction treatment, followed by a maintenance treatment. The median total duration was 12 months (range: 3-30). Eleven patients received steroids concomitantly. Fifteen patients achieved an objective response; five had a complete response (CR: 25%), ten had a partial response (PR: 50%), four had stable disease (SD: 20%) and one patient progressed (PD: 5%). Of interest, four out of the six patients who received VBL without concomitant steroids achieved an objective response. With a median follow-up of 6.8 years, the 5-year event-free and overall survival was 61% and 84%, respectively. VBL was well-tolerated and there were no patient withdrawals due to adverse events. VBL, with or without steroids, could potentially be a useful therapeutic option in LCH with CNS mass lesions, especially for those with inoperable lesions or multiple lesions. Prospective clinical trials are warranted for the evaluation of VBL in this indication.
  Orphanet Journal of Rare Diseases 12/2011; 6(1):83. · 5.83 Impact Factor
• Article: Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin's lymphoma - an Anglo-French collaborative report.

  Ananth Shankar, Georgina W Hall, Stephanie Gorde-Grosjean, Dirk Hasenclever, Thierry Leblanc, Janis Hayward, Anne Lambilliotte, Stephen Daw, Yves Perel, Keith McCarthy, Odile Lejars, Aurore Coulomb, W Odile Oberlin, W Hamish Wallace, Judith Landman-Parker
  [show abstract] [hide abstract]
  ABSTRACT: To examine whether three cycles of a low-intensity chemotherapy consisting of cyclophosphamide [500 mg/m(2) - day 1], vinblastine [6 mg/m(2) - days 1 and 8] and prednisolone [40 mg/m(2) - days 1-7] (CVP) is safe and therapeutically effective in children and adolescents with early stage nodular lymphocyte predominant Hodgkin lymphoma [nLPHL]. Fifty-five children and adolescents with early stage nLPHL [median age 13 years, range 4-17 years] diagnosed between June 2005 and October 2010 in the UK and France are the subjects of this report. Staging investigations included conventional cross sectional as well as 18 fluro-deoxyglucose [FDG] PET imaging. Histology was confirmed as nLPHL by an expert pathology panel. Of the 45 patients, who received CVP as first line treatment, 36 [80%, 95% Confidence Interval [CI]: (68; 92)] either achieved a complete remission [CR] or CR unconfirmed [CRu], the remaining nine patients achieved a partial response. All nine subsequently achieved CR with salvage chemotherapy [n=7] or radiotherapy [n=2]. Ten patients received CVP at relapse after primary treatment that consisted of surgery alone and all achieved CR. To date, only three patients have relapsed after CVP chemotherapy and all had received CVP as first line treatment at initial diagnosis. The 40-month freedom from treatment failure and overall survival for the entire cohort were 75.4% (SE ± 6%) and 100%, respectively. No significant early toxicity was observed. Our results show that CVP is an effective chemotherapy regimen in children and adolescents with early stage nLPHL that is well tolerated with minimal acute toxicity.
  European journal of cancer (Oxford, England: 1990) 11/2011; 48(11):1700-6. · 4.12 Impact Factor
• Article: Childhood hodgkin's lymphoma, non‐hodgkin's lymphoma and factors related to the immune system: The escale study (SFCE)

  Jérémie Rudant, Laurent Orsi, Alain Monnereau, Catherine Patte, Hélène Pacquement, Judith Landman-Parker, Christophe Bergeron, Alain Robert, Gérard Michel, Anne Lambilliotte, Nathalie Aladjidi, Virginie Gandemer, Patrick Lutz, Geneviève Margueritte, Dominique Plantaz, Françoise Méchinaud, Denis Hémon, Jacqueline Clavel
  [show abstract] [hide abstract]
  ABSTRACT: The study investigated the role of factors considered related to the early stimulation of the immune system in the aetiology of childhood lymphoma. The national registry-based case–control study, Escale, was carried out in France over the period 2003–2004. Population controls were frequency matched with the cases on age and gender. Data were obtained from structured telephone questionnaires administered to mothers. Odds ratios (ORs) were estimated using unconditional regression models adjusted for potential confounders. Data from 128 cases of Hodgkin's lymphoma (HL) aged 5–14 years, 164 cases of non-Hodgkin's lymphoma (NHL) aged 2–14 years and 1,312 controls were analyzed. Negative associations were observed between HL and day care attendance [OR = 0.5 (0.2–1.2)] and between HL and repeated early common infections among non-breastfed children [OR = 0.3 (.2–0.7), p = 0.003] [OR for breastfed children: 1.0 (.5–2.1)], but not for the other factors investigated. Negative associations were observed between NHL and birth order 3 or more [OR = 0.7 (0.4–1.1)], prolonged breastfeeding [OR = 0.5 (0.3–1.0)], regular contact with farm animals [OR = 0.5 (0.3–1.0)], frequent farm visits in early life [OR = 0.6 (0.4–1.1)] and history of asthma [OR = 0.6 (0.3–1.1)]. In conclusion, the results partly support the hypothesis that an abnormal maturation of the immune system may play a role in childhood HL or NHL, and call for further investigations.
  International Journal of Cancer 03/2011; 129(9):2236 - 2247. · 5.44 Impact Factor
• Article: Childhood acute leukemia, early common infections, and allergy: The ESCALE Study.

  Jérémie Rudant, Laurent Orsi, Florence Menegaux, Arnaud Petit, André Baruchel, Yves Bertrand, Anne Lambilliotte, Alain Robert, Gérard Michel, Geneviève Margueritte, Julie Tandonnet, Françoise Mechinaud, Pierre Bordigoni, Denis Hémon, Jacqueline Clavel
  [show abstract] [hide abstract]
  ABSTRACT: This study investigated the role of factors considered related to early stimulation of the immune system in the etiology of childhood acute leukemia. The national registry-based case-control study ESCALE was carried out in France in 2003-2004. Population controls were frequency matched to cases on age and gender. Data were obtained from structured telephone questionnaires administered to mothers. Odds ratios were estimated using unconditional regression models adjusted for potential confounders. Included were 634 acute lymphoblastic leukemia cases, 86 acute myeloblastic leukemia cases, and 1,494 controls aged ≥1 year. Negative associations were observed between acute lymphoblastic leukemia and birth order (P for trend < 0.0001), attendance at a day-care center before age 1 year (odds ratio (OR) = 0.8, 95% confidence interval (CI): 0.6, 1.1), prolonged breastfeeding (OR = 0.7, 95% CI: 0.5, 1.0), repeated early common infections (OR = 0.7, 95% CI: 0.6, 0.9), regular contact with farm animals (OR = 0.6, 95% CI: 0.5, 0.8), frequent farm visits in early life (OR = 0.4, 95% CI: 0.3, 0.6), and history of asthma (OR = 0.7, 95% CI: 0.4, 1.0) or eczema (OR = 0.7, 95% CI: 0.6, 0.9). Results support the hypothesis that repeated early infections and asthma may play a role against childhood acute leukemia.
  American journal of epidemiology 11/2010; 172(9):1015-27. · 5.59 Impact Factor
• Article: Childhood hematopoietic malignancies and parental use of tobacco and alcohol: the ESCALE study (SFCE).

  Jérémie Rudant, Florence Menegaux, Guy Leverger, André Baruchel, Anne Lambilliotte, Yves Bertrand, Catherine Patte, Hélène Pacquement, Cécile Vérité, Alain Robert, Gérard Michel, Geneviève Margueritte, Virginie Gandemer, Denis Hémon, Jacqueline Clavel
  [show abstract] [hide abstract]
  ABSTRACT: Investigating the role of parental smoking and maternal alcohol consumption in the etiology of childhood hematopoietic malignancies. The national registry-based case-control study ESCALE was carried out in France over the period 2003-2004. Population controls were frequency matched with the cases on age and gender. Maternal smoking and alcohol consumption during pregnancy and paternal smoking since before conception were reported by the mothers in a structured telephone questionnaire. Odds ratios (OR) were estimated using unconditional regression models closely adjusted for potential confounders. A total of 765 cases of acute leukemia (AL), 130 of Hodgkin's lymphoma (HL), 165 of non-Hodgkin's lymphoma (NHL) and 1681 controls were included. Paternal smoking was significantly associated with childhood ALL (OR = 1.4 [1.1-1.7]), AML (OR = 1.5 [1.0-2.3]), Burkitt (OR = 2.0 [1.2-3.2]), and anaplastic large cell (OR = 3.2 [1.2-9.1]) NHL. For the four diseases, the ORs significantly increased with the number of cigarettes smoked. No association with HL or with other types of NHL was observed. The associations with maternal alcohol consumption and cigarette smoking during pregnancy were less consistent. The results support the hypothesis that only paternal smoking, and not maternal alcohol consumption or cigarette smoking, plays a role in childhood hematopoietic malignancies.
  Cancer Causes and Control 08/2008; 19(10):1277-90. · 2.88 Impact Factor
• Article: Childhood leukaemia, polymorphisms of metabolism enzyme genes, and interactions with maternal tobacco, coffee and alcohol consumption during pregnancy.

  Jacqueline Clavel, Stéphanie Bellec, Sandra Rebouissou, Florence Ménégaux, Jean Feunteun, Catherine Bonaïti-Pellié, André Baruchel, Kamila Kebaili, Anne Lambilliotte, Guy Leverger, Danièle Sommelet, Brigitte Lescoeur, Philippe Beaune, Denis Hémon, Marie-Anne Loriot
  [show abstract] [hide abstract]
  ABSTRACT: Metabolic polymorphisms may influence the risk of childhood leukaemia related to maternal tobacco, coffee or alcohol consumption. The data were extracted from a case-control study including 280 cases of acute leukaemia and 288 controls. Blood sampling was obtained for a representative subset of 219 cases and 105 controls. Gene-environment interactions were estimated using both case-control and case-only analyses. The polymorphisms of CYP1A1, GSTM1, GSTP1, GSTT1 and NQO1 were not associated with the risk of leukaemia. The slow EPHX1 allele was negatively associated with childhood leukaemia while an inverse non-significant association was observed with the fast EPHX1 allele. Maternal smoking during pregnancy was not related to leukaemia, but an interaction was observed in the case-only analysis with CYP1A1*2A variant allele (odds ratio (OR) 2.2 [1.0-4.9]) and with GSTM1 deletion (OR 2.3 [1.2-4.4]). Conversely, coffee drinking interacted negatively with NQO1 polymorphism in the case-only analysis (OR 0.6 [0.3-1.2] and 0.4 [0.1-1.0] for light and heavy coffee consumptions, respectively). This study suggests that maternal smoking may be a risk factor for leukaemia in children who carry CYP1A1 or GSTM1 genotypes, which might increase reactive metabolites of polycyclic aromatic hydrocarbons.
  European Journal of Cancer Prevention 01/2006; 14(6):531-40. · 2.13 Impact Factor